India's pharmaceutical industry is a global heavyweight, supplying about 20% of the world's generic drugs by volume and underpinning major vaccine campaigns that deliver affordable medicine across developing nations. Yet a June 2026 report from NITI Aayog, the government's premier think tank, reveals that this export prowess masks a structural vulnerability: the sector's critical inputs are overwhelmingly sourced from China.
The report, published in the Trade Watch Quarterly, finds that India relies on China for over 65% of its key starting materials (KSMs) and active pharmaceutical ingredients (APIs) — the chemical core of any medicine. For entire classes of life-saving drugs, including antibiotics and antipyretics, that dependency exceeds 85%. This is not a balanced trade relationship but a precarious pipeline: a single geopolitical tremor, trade dispute, or lockdown at a Chinese port could sever these supply lines, triggering a public health crisis in India and among the many developing countries that depend on its affordable generics.
Pharmacy of the World, Made in China
India's self-image as the "Pharmacy of the World" now carries an implicit Made in China warning. The Narendra Modi government has championed "Atmanirbhar Bharat" (self-reliant India) and promoted local manufacturing through production-linked incentive (PLI) schemes. But the NITI Aayog report underscores the gap between political rhetoric and industrial reality. While India's pharmaceutical companies have built world-class formulation and export capabilities, they have not invested commensurately in upstream chemical synthesis. Chinese manufacturers, benefiting from economies of scale, state subsidies, and integrated supply chains, have become the default suppliers of KSMs and APIs.
This dependence is not accidental. Over the past two decades, Chinese firms have captured the bulk of global API production, driven by lower environmental compliance costs and aggressive industrial policy. India's pharmaceutical sector, focused on high-margin generics and branded drugs, outsourced the low-margin, high-pollution precursor manufacturing to China. The result is a supply chain that is efficient in normal times but brittle under stress.
The report's findings echo concerns raised during the COVID-19 pandemic, when India faced shortages of key drug ingredients after China imposed lockdowns. In 2020, New Delhi restricted exports of 26 pharmaceutical ingredients to secure domestic supplies, but the underlying dependency remained unaddressed. The NITI Aayog analysis suggests that despite subsequent PLI schemes for bulk drugs, the gap has not closed.
India's vulnerability is part of a broader pattern across Asia. Many regional economies have become enmeshed in Chinese supply chains, from electronics to rare earths. For a deeper look at how Chinese investment shapes industrial booms elsewhere, see our earlier report: China Built Indonesia's Nickel Boom. Will It Stay for the Bust?
The Modi government faces a strategic choice. It can continue to rely on Chinese inputs, accepting the risk of disruption, or it can invest heavily in domestic API production, which would require significant capital, technology transfer, and environmental management. The latter path would align with the "Made in India" narrative but would take years to yield results. Meanwhile, the pharmaceutical industry's global reputation — built on affordability and reliability — hangs in the balance.
For now, the NITI Aayog report serves as a stark reminder: India's pharmaceutical success story is real, but its foundation is imported. The question is not whether India can produce medicines, but whether it can produce them without depending on a single, geopolitically fraught supplier.
